Vetnuus | May 2024 17 The benefits of allogeneic MSCs over autologous Stromal Vascular Fraction 1. Reliable quantities of stem cells in every ml 2. Guarantee that the cells being administered are viable stem cells: flow cytometry carried out on every batch tests for the absence of leukocytes and the presence of the markers of viable stem cells. 3. Absence of MHC markers that would identify cells as originating from a different host 4. Ease of preparation since the cells arrive ready for administration. 5. Significantly lower cost than for SVF – less than half the cost in most markets and most animals. While PRP treatment needs to be administered every 6 months to retain its effect, a single administration of allogeneic stem cells has been shown to have a duration of effect of significantly over 2 years – up to 5 years in some studies, yet the cost is generally lower than a year of treatment with PRP (Alves 2021, Kriston-Pál 2020) Taking the step into the future: what to know before applying allogeneic MSCs for the first time Allogeneic MSCs are contraindicated in patients with active infections, and not recommended for patients with a history of neoplasia, but may become a valuable new tool to enhance quality of life for our patients. References Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N, et al. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis Vet J. 2009;179(1):10–24. Alves, J.C., Santos, A. & Jorge, P. Platelet-rich plasma therapy in dogs with bilateral hip osteoarthritis. BMC Vet Res 17, 207 (2021). https://doi.org/10.1186/s12917-021-02913-x Kriston-Pál É, Haracska L, Cooper P, Kiss-Tóth E, Szukacsov V, Monostori É. A Regenerative Approach to Canine Osteoarthritis Using Allogeneic, Adipose-Derived Mesenchymal Stem Cells. Safety Results of a LongTerm Follow-Up. Front Vet Sci. 2020 Aug 13;7:510. doi: 10.3389/ fvets.2020.00510. PMID: 32903517; PMCID: PMC7438407. Conflict of interest statement: The author is a shareholder in a company that manufactures allogeneic MSCs for veterinary use. This article was sponsored by V-Tech, the agent that supplies VetRenew stem cells (www.vetrenew.co.za) in Southern Africa. For more information or product support contact your local V-Tech representative or Customer Care on +27 87 250 5925 / info@v-tech.com. v We compound veterinary medicines www.v-tech.co.za / Tel: +27 87 150 5925 (SA) Figure 1: an example of a flow cytometry batch analysis on allogeneic stem cells. CD29 and CD90 surface markers indicate the presence of viable stem cells, absence of CD34 and CD45 markers indicates the absence of angiogenitor- and white blood cells. Article
RkJQdWJsaXNoZXIy OTc5MDU=